3,359 results match your criteria t1d patients

Vitamin D pathway gene polymorphisms, vitamin D level, and cytokines in children with type 1 diabetes.

Gene 2021 May 4:145691. Epub 2021 May 4.

Siriraj Diabetes Center of Excellence, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of Endocrinology and Metabolism, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address:

Aims: The study aimed to examine genetic polymorphism of vitamin D-related genes and association between those genes and vitamin D and cytokines levels in children with type 1 diabetes (T1D).

Materials And Methods: This study was conducted among 100 T1D children and 100 controls at Division of Endocrinology and Metabolism, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, during 2016 to 2018. Vitamin D metabolite levels were measured by liquid chromatography-tandem mass spectrometry method, serum cytokine levels of IFN- ɣ, IL-10, IL-13, IL-17α, IL-2, IL-4, IL-6, and TNF-α by immunoassay, and genetic variations at VDR, CYP2R1, CYP27B1, GC, DHCR7, and CYP24A1 by polymerase chain reaction-restriction fragment length polymorphism method. Read More

View Article and Full-Text PDF

Establishment of a novel double-monoclonal antibody sandwich enzyme-linked immunosorbent assay (ELISA): Tool for human B7-H4 detection in autoimmune diseases.

Clin Exp Immunol 2021 May 7. Epub 2021 May 7.

Jiangsu Institute of Clinical Immunology & Jiangsu Key Laboratory of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China.

B7-H4, one of the immunoregulatory proteins, plays an inhibitory role by inhibiting T cell proliferation and cytokine production. Nevertheless, the significance of soluble B7-H4 (sB7-H4) in autoimmune diseases is unclear. In our study, we developed two novel mouse anti-human B7-H4 monoclonal antibodies (mAbs) (clone 8D4 and 7E1) with utilities for flow cytometry, immunoblotting and immunofluorescence. Read More

View Article and Full-Text PDF

Accurate prediction of HbA1c by continuous glucose monitoring using a kinetic model with patient-specific parameters for red blood cell lifespan and glucose uptake.

Diab Vasc Dis Res 2021 May-Jun;18(3):14791641211013734

Abbott Diabetes Care, Alameda, CA, USA.

Background: A recent kinetic model proposed a new individualized glycaemic marker, calculated HbA1c (cHbA1c), based on kinetic parameters and glucose levels that are specific to each person. The aims of the current work were to validate the accuracy of this glucose metric for clinical use and evaluate data requirements for the estimation of personal kinetic factors.

Methods: We retrieved HbA1c and glucose data from a group of 51 Japanese T1D patients under sensor-augmented pump (SAP) therapy. Read More

View Article and Full-Text PDF

The Role of Programmed Death-1 in Type 1 Diabetes.

Curr Diab Rep 2021 May 6;21(6):20. Epub 2021 May 6.

Department of Medicine, Center for Immunology, University of Minnesota Medical School, 2101 6th St SE, Wallin Medical Biosciences Building, 3-146, Minneapolis, MN, 55455, USA.

Purpose Of Review: Programmed death-1 (PD-1) is an inhibitory receptor that controls T and B cell proliferation and function through interacting with its ligand PD-L1 or PD-L2. PD-1/PD-L1 blockade reboots anti-tumor immunity and is currently used to treat > 15 different types of cancer. However, the response rate is not at 100% and some patients relapse. Read More

View Article and Full-Text PDF

FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction.

Endocrinology 2021 May 5. Epub 2021 May 5.

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.

Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor (FGF) family of proteins. The biological activity of FGF21 was first shown to induce insulin independent glucose uptake in adipocytes through the GLUT1 transporter. Subsequently, it was shown to have effects on the liver to increase fatty acid oxidation. Read More

View Article and Full-Text PDF

Associated Autoimmunity in Type 1 Diabetes and Latent Autoimmune Diabetes of Adults: The Role of Glutamic-Acid Decarboxylase Autoantibodies.

Diabetes Res Clin Pract 2021 May 1:108847. Epub 2021 May 1.

Diabetes and Metabolism Clinic, 2(nd) Department of Pediatrics, National and Kapodistrian University of Athens, "P&A Kyriakou" Children's Hospital, Athens, Greece.

Aims: To determine the prevalence of Associated Autoimmune Diseases (AADs) in Latent Autoimmune Diabetes of Adults (LADA) versus autoimmune Type 1 Diabetes (T1D) and the role of glutamic-acid decarboxylase antibodies (GADA) and other factors.

Methods: Adults with autoimmune diabetes mellitus (DM) were recruited from the Diabetes Center of Nikaia-Piraeus Hospital. Demographic and clinical parameters were recorded and anti-pancreatic and organ-specific antibodies were measured. Read More

View Article and Full-Text PDF

Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients.

Arch Endocrinol Metab 2021 Apr 29. Epub 2021 Apr 29.

Departamento de Nutrologia e Diabetes, Universidade Federal do Rio de Janeiro, RJ, Brasil.

Objective: Adipose tissue-derived stromal/stem cells (ASCs) and vitamin D have immunomodulatory actions that could be useful for type 1 diabetes (T1D). We aimed in this study to investigate the safety and efficacy of ASCs + daily cholecalciferol (VIT D) for 6 months in patients with recent-onset T1D.

Methods: In this prospective, dual-center, open trial, patients with recent onset T1D received one dose of allogenic ASC (1 × 10 cells/kg) and cholecalciferol 2,000 UI/day for 6 months (group 1). Read More

View Article and Full-Text PDF

Characteristics of type 1 diabetes mellitus in children and adolescents with Down's syndrome in an admixed population.

Arch Endocrinol Metab 2021 Apr 29. Epub 2021 Apr 29.

Serviço de Endocrinologia Pediátrica, Departamento de Pediatria, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brasil,

Objective: People with Down's syndrome (DS) have a higher risk of developing type 1 diabetes mellitus (T1D) and may have specific clinical features compared to T1D patients without DS. This study evaluated the clinical and laboratory aspects of T1D in children and adolescents with DS in an admixed population.

Methods: A case-control study comparing patients with T1D and DS (T1D+DS) to patients with T1D without DS (T1D controls) from two tertiary academic Hospitals in São Paulo, Brazil. Read More

View Article and Full-Text PDF

Potential Mimicry of Viral and Pancreatic β Cell Antigens Through Non-Spliced and -Spliced Epitope Candidates in Type 1 Diabetes.

Front Immunol 2021 15;12:656451. Epub 2021 Apr 15.

Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany.

Increasing evidence suggests that post-translational peptide splicing can play a role in the immune response under pathological conditions. This seems to be particularly relevant in Type 1 Diabetes (T1D) since post-translationally spliced epitopes derived from T1D-associated antigens have been identified among those peptides bound to Human Leucocyte Antigen (HLA) class I and II complexes. Their immunogenicity has been confirmed through CD4 and CD8 T cell-mediated responses in T1D patients. Read More

View Article and Full-Text PDF

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.

Front Immunol 2021;12:656362. Epub 2021 Apr 15.

Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences (DIBIC) L. Sacco, Università degli Studi di Milano, Milan, Italy.

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i. Read More

View Article and Full-Text PDF

In Vivo Confocal Microscopy Study of Corneal Nerve Alterations in Children and Youths with Type 1 Diabetes.

Pediatr Diabetes 2021 May 2. Epub 2021 May 2.

Department of Neuroscience, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.

Objective: To determine whether children and youths with type 1 diabetes (T1D) have early alterations of the corneal subbasal nerve plexus detectable with In vivo confocal microscopy (IVCM) and to investigate the role of longitudinally measured major risk factors for diabetes complications associated with these alterations.

Methods: One hundred and fifty children and youths with T1D and 51 age-matched controls were enrolled and underwent IVCM. Corneal nerve fiber length (CNFL), corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), corneal fiber total branch density (CTBD), and corneal fiber fractal dimension (CNFrD) were measured. Read More

View Article and Full-Text PDF

Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study.

Diabetes Ther 2021 May 1. Epub 2021 May 1.

Division of Endocrinology and Metabolism, Department of Medicine, Dalhousie University, Halifax, Canada.

Introduction: The aim of the study was to examine glycaemic control and safety of insulin degludec (degludec) in patients with either type 1 diabetes (T1D) or type 2 diabetes (T2D) under routine care settings in Canada.

Methods: Data were extracted from medical records of adults with T1D or T2D who switched to degludec (± prandial insulin) from another basal insulin (± prandial insulin) ≥ 6 months prior to data collection. The primary endpoint was change in glycated haemoglobin (HbA) at 6 ± 3 months after degludec initiation. Read More

View Article and Full-Text PDF

Three-phasic pattern of C-peptide decline in type 1 diabetes patients with partial remission.

Diabetes Metab Res Rev 2021 Apr 29. Epub 2021 Apr 29.

Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Aims: To explore the different patterns of C-peptide decline in patients with and without partial remission of newly diagnosed type 1 diabetes (T1D).

Materials And Methods: A total of 298 patients with new-onset T1D were followed up regularly at 3 months' interval to investigate the loss of C-peptide. Partial remission was determined by postprandial C-peptide ≥300 pmol/L or insulin dose-adjusted A1c ≤ 9 in the absence of C-peptide. Read More

View Article and Full-Text PDF

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.

Pharmaceutics 2021 Apr 2;13(4). Epub 2021 Apr 2.

Boehringer Ingelheim International GmbH, 55216 Ingelheim, Germany.

In clinical trials, sodium-glucose co-transporter (SGLT) inhibitor use as adjunct to insulin therapy in type 1 diabetes (T1D) provides glucometabolic benefits while diabetic ketoacidosis risk is increased. The SGLT2 inhibitor empagliflozin was evaluated in two phase III trials: EASE-2 and EASE-3. A low, 2. Read More

View Article and Full-Text PDF

Clinical Characteristics and Degree of Glycemic and Cardiovascular Risk Factor Control in Patients with Type 1 Diabetes in Catalonia (Spain).

J Clin Med 2021 Apr 6;10(7). Epub 2021 Apr 6.

DAP-Cat Group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), 08007 Barcelona, Spain.

Background: This study aims to evaluate the clinical characteristics, complications, degree of glycemic control, and cardiovascular risk factor control in patients with type 1 diabetes in Catalonia (Northwest of Spain).

Methods: Cross-sectional study using a database including clinical, laboratory, and treatment data. Patients with an ICD10 diagnosis of type 1 diabetes were included, excluding those treated with glucose-lowering agents other than insulin, or treated only with basal insulin two years after diagnosis. Read More

View Article and Full-Text PDF

Comparing Two Treatment Approaches for Patients with Type 1 Diabetes During Aerobic Exercise: a Randomised, Crossover Study.

Sports Med Open 2021 Apr 29;7(1):29. Epub 2021 Apr 29.

Waikato Medical Research Centre, Te Huataki Waiora, School of Health, University of Waikato, Hamilton, New Zealand.

Background: In a randomised, counterbalanced, crossover design, eight men with type 1 diabetes (T1D; mean ± SD age, 27.6 ± 11.4 years) reduced insulin (INS) by 50% of their normal dose or consumed carbohydrates equivalent to 1 g of carbohydrate per kilogramme of their body weight without the usual insulin bolus (CARBS) over two sessions, held a week apart. Read More

View Article and Full-Text PDF

Treating Type 1 Diabetes by Pancreas Transplant Alone: a Cohort Study on Actual Long-Term (10 Years) Efficacy and Safety.

Transplantation 2021 Jan 19. Epub 2021 Jan 19.

1Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy 2Division of General and Transplant Surgery, Cisanello University Hospital, Pisa, Italy 3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy 4Diabetes Unit, Versilia Hospital, Azienda ASL Area Vasta Nord-Ovest, Lido di Camaiore, Lucca, Italy 5Departmental Section of Endocrinology and Metabolism of Organ and Cellular Transplantation, Cisanello University Hospital, Pisa, Italy 6Division of Nephrology, Cisanello University Hospital, Pisa, Italy 7Department of Surgical, Medical, Molecular Pathology and Critical Area, Division of Surgical Pathology, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy.

Background: Physiologically regulated insulin secretion and euglycemia are achievable in type 1 diabetes (T1D) by islet or pancreas transplantation. However, pancreas transplant alone (PTA) remains a debated approach, with uncertainties on its relative benefits and risks. We determined the actual long-term (10 years) efficacy and safety of PTA in carefully characterized T1D subjects. Read More

View Article and Full-Text PDF
January 2021

Hypoglycemia frequency and treatment satisfaction in patients receiving insulin analogues for treatment of type 1 diabetes mellitus.

Arch Endocrinol Metab 2021 Feb 24. Epub 2021 Feb 24.

Programa de Pós-Graduação em Endocrinologia, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brasil.

Objective: The aim of this study was to evaluate the frequency of hypoglycemia and the treatment satisfaction in patients with type 1 diabetes (T1D) using insulin analogues.

Methods: This observational retrospective study included 516 adult patients with T1D from 38 cities in Southern Brazil. Demographics and clinical data were collected using a self-report questionnaire. Read More

View Article and Full-Text PDF
February 2021

The effect of COVID-19 pandemic on the lifestyle and glycemic control in patients with type 1 diabetes: a retrospective cohort study.

Diabetol Int 2021 Apr 19:1-6. Epub 2021 Apr 19.

Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566 Japan.

Background: To investigate the acute effects of coronavirus disease (COVID-19) on lifestyle and metabolic parameters in patients with type 1 diabetes (T1D).

Methods: This retrospective cohort study included 34 patients who were admitted to our hospital from April 16 to May 1, 2020. Data on stress levels, sleep duration, exercise, total diet, snacks, and prepared food intake were obtained from the questionnaires. Read More

View Article and Full-Text PDF

Decreased expression of programmed death-1 on CD8 effector memory T lymphocytes correlates with the pathogenesis of type 1 diabetes.

Acta Diabetol 2021 Apr 23. Epub 2021 Apr 23.

Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou, China.

Aims: Chronic inflammation of autoimmune diseases, including type 1 diabetes (T1D), is mainly mediated by memory T(Tm) cells, predominantly effector memory T (Tem) cells. The roles of the programmed death-1 (PD-1) receptor on lymphocytes have been well studied in tumor and other infection models. However, little is known about the relationship between the expression of PD-1 on CD8 Tem cells and the pathogenesis of T1D. Read More

View Article and Full-Text PDF

Prevalence of bone fracture and its association with severe hypoglycemia in Japanese patients with type 1 diabetes.

BMJ Open Diabetes Res Care 2021 Apr;9(1)

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Introduction: Type 1 diabetes (T1D) is associated with higher fracture risk. However, few studies have investigated the relationship between severe hypoglycemia and fracture risk in patients with T1D, and the results are controversial. Besides, none has investigated the risk factors for fracture in Asian patients with T1D. Read More

View Article and Full-Text PDF

Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study.

Diabetes Care 2021 Apr 21. Epub 2021 Apr 21.

Biostatistics Center, George Washington University, Rockville, MD.

Objective: The role of genetic factors in the risk of cardiovascular disease (CVD) for patients with type 1 diabetes (T1D) remains unknown. We therefore examined whether previously identified genetic factors for coronary artery disease (CAD) are associated with the risk of CVD above and beyond established demographic and clinical factors in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Research Design And Methods: Polygenic risk scores (PRS) and individual genetic variants identified in previous studies were obtained from genome-wide genotyping performed in 1,371 DCCT/EDIC participants. Read More

View Article and Full-Text PDF

The antroduodenal transition time is prolonged in adults with type 1 diabetes.

Neurogastroenterol Motil 2021 Apr 21:e14144. Epub 2021 Apr 21.

Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.

Background: The gastroparetic syndrome encompasses antral hypomotility, gastric dysrhythmia, impaired antroduodenal coordination, pyloric dysfunction, and abnormal duodenal motility; the last three collectively referred to as pylorospasms. We hypothesized that antroduodenal motility is diminished and transition time is prolonged in adults with type 1 diabetes (T1D) and polyneuropathy.

Methods: This cross-sectional study included 124 participants, of which 21 were healthy, 53 had T1D and 50 had T1D with distal symmetrical polyneuropathy (T1D + DSPN). Read More

View Article and Full-Text PDF

Nomogram development and validation to predict hepatocellular carcinoma tumor behavior by preoperative gadoxetic acid-enhanced MRI.

Eur Radiol 2021 Apr 20. Epub 2021 Apr 20.

Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road 2, Guangzhou, 510080, China.

Objectives: Pretreatment evaluation of tumor biology and microenvironment is important to predict prognosis and plan treatment. We aimed to develop nomograms based on gadoxetic acid-enhanced MRI to predict microvascular invasion (MVI), tumor differentiation, and immunoscore.

Methods: This retrospective study included 273 patients with HCC who underwent preoperative gadoxetic acid-enhanced MRI. Read More

View Article and Full-Text PDF

Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed 670G hybrid closed-loop system in simulated trials compared to NovoLog®.

Comput Methods Programs Biomed 2021 Apr 8;205:106087. Epub 2021 Apr 8.

Medtronic Diabetes, United States.

Introduction: Medtronic has developed a virtual patient simulator for modeling and predicting insulin therapy outcomes for people with type 1 diabetes (T1D). An enhanced simulator was created to estimate outcomes when using the MiniMed 670G system with standard NovoLog® (EU: NovoRapid, US: NovoLog) versus Fiasp ® by using clinical data.

Methods: Sixty-seven participants' PK profiles were generated per type of insulin (Total of 134 PK profiles). Read More

View Article and Full-Text PDF

Differential effects of minocycline on microvascular complications in murine models of type 1 and type 2 diabetes.

J Transl Sci 2021 Feb 16;7(1). Epub 2020 Jun 16.

Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.

Diabetes is a global healthcare problem associated with enormous healthcare and personal costs. Despite glucose lowering agents that control glycaemia, both type 1 (T1D) and type (T2D) diabetes patients often develop microvascular complications that increase morbidity and mortality. Current interventions rely on careful glycemic control and healthy lifestyle choices, but these are ineffective at reversing or completely preventing the major microvascular complications, diabetic peripheral neuropathy (DPN), diabetic retinopathy (DR), and diabetic kidney disease (DKD). Read More

View Article and Full-Text PDF
February 2021

Serum Levels of Inflammatory Proteins Are Associated With Peripheral Neuropathy in a Cross-Sectional Type-1 Diabetes Cohort.

Front Immunol 2021 31;12:654233. Epub 2021 Mar 31.

Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA, United States.

Chronic low-grade inflammation is involved in the pathogenesis of type-1 diabetes (T1D) and its complications. In this cross-section study design, we investigated association between serum levels of soluble cytokine receptors with presence of peripheral neuropathy in 694 type-1 diabetes patients. Sex, age, blood pressure, smoking, alcohol intake, HbA1c and lipid profile, presence of DPN (peripheral and autonomic), retinopathy and nephropathy was obtained from patient's chart. Read More

View Article and Full-Text PDF

Early left ventricular systolic dysfunction in asymptomatic patients with type 1 diabetes: a single-center, pilot study.

J Diabetes Complications 2021 Jun 20;35(6):107913. Epub 2021 Mar 20.

First Department of Propaedeutic Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Aims: Prevalence and risk factors of pre-symptomatic left ventricular systolic dysfunction (LVSD) in individuals with type 1 diabetes (T1D) have not been adequately studied. The present cross-sectional study assessed the prevalence of early LVSD in asymptomatic patients with type 1 diabetes and investigated potential risk factors.

Methods: Consecutive patients with T1D, free of cardiovascular disease and significant evident microvascular complications were examined. Read More

View Article and Full-Text PDF

Effects of remote care of patients with poorly controlled type 1 diabetes included in an experimental telemonitoring programme.

Diabetes Metab 2021 Apr 13:101251. Epub 2021 Apr 13.

DIAB-eCARE Diabetes Center, Hospices Civils de Lyon, France. Electronic address:

Aim: To assess, in a real-life setting, the effectiveness of telemonitoring adults with type 1 diabetes (T1D) using continuous glucose monitoring in a telemedical experiment.

Methods: Experimentation in Telemedicine for the Improvement of Healthcare Pathways (ETAPES), an experimental telehealth programme for five chronic diseases, is supported by the French national healthcare system to promote telemedical care. Using data from a single university hospital centre, 72 adults were studied, including 42 subjects (58%) receiving insulin pump therapy and 30 (42%) receiving multiple daily injections, with a median age of 35. Read More

View Article and Full-Text PDF

Rapid Adoption of Telemedicine Along with Emergent Use of Continuous Glucose Monitors in the Ambulatory Care of Young Persons with New-Onset Type 1 Diabetes in the Time of COVID-19: A Case Series.

Telemed J E Health 2021 Apr 15. Epub 2021 Apr 15.

Section on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston, Massachusetts, USA.

The COVID-19 pandemic has caused strain on hospital systems and potential delay in diagnosis of type 1 diabetes (T1D). Outpatient diagnosis and treatment of metabolically stable young persons with new-onset T1D have been shown to be equivalent to inpatient. We describe an approach to outpatient management of newly diagnosed T1D during the COVID-19 pandemic using an interdisciplinary team, telemedicine, and diabetes technologies including rapid implementation of continuous glucose monitoring (CGM). Read More

View Article and Full-Text PDF